|
[1]CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the american association for the study of liver diseases[J].Hepatology, 2017.[Epub ahead of print]
|
|
[2]LOOMBA R, SANYAL AJ.The global NAFLD epidemic[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (11) :686-690.
|
|
[3]ABENAVOLI L, MILIC N, di RENZO L, et al.Metabolic aspects of adult patients with nonalcoholic fatty liver disease[J].World JGastroenterol, 2016, 22 (31) :7006-7016.
|
|
[4]BUZZETTI E, PINZANI M, TSOCHATZIS EA.The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) [J].Metabolism, 2016, 65 (8) :1038-1048.
|
|
[5]HAAS JT, FRANCQUE S, STAELS B, et al.Pathophysiology and mechanisms of nonalcoholic fatty liver disease[J].Annu Rev Physiol, 2016, 78:181-205.
|
|
[6]LOOMBA R, ABRAHAM M, UNALP A, et al.Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis[J].Hepatology, 2012, 56 (3) :943-951.
|
|
[7]POLYZOS SA, KOUNTOURAS J, MANTZOROS CS.Adipokines in nonalcoholic fatty liver disease[J].Metabolism, 2016, 65 (8) :1062-1079.
|
|
[8]GULCELIK NE, HALIL M, ARIOGUL S, et al.Adipocytokines and aging:adiponectin and leptin[J].Minerva Endocrinol, 2013, 38 (2) :203-210.
|
|
[9]BERTOLANI C, MARRA F.The role of adipokines in liver fibrosis[J].Pathophysiology, 2008, 15 (2) :91-101.
|
|
[10]SINGH R, KAUSHIK S, WANG Y, et al.Autophagy regulates lipid metabolism[J].Nature, 2009, 458:1131-1135.
|
|
[11]ROLO AP, TEODORO JS, PALMEIRA CM.Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis[J].Free Radic Biol Med, 2012, 52 (1) :59-69.
|
|
[12]GUSDON AM, SONG KX, QU S.Nonalcoholic Fatty liver disease:pathogenesis and therapeutics from a mitochondria-centric perspective[J].Oxid Med Cell Longev, 2014, 2014:637027.
|
|
[13]FERRAMOSCA A, di GIACOMO M, ZARA V.et al.Antioxidant dietary approach in treatment of fatty liver:new insights and updates[J].World J Gastroenterol, 2017, 23 (23) :4146-4157.
|
|
[14]SPAHIS S, DELVIN E, BORYS JM, et al.Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis[J].Antioxid Redox Signal, 2017, 26 (10) :519-541.
|
|
[15]TAKAKI A, KAWAI D, YAMAMOTO K.Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH) [J].Int J Mol Sci, 2013, 14 (10) :20704-20728.
|
|
[16]DIXON LJ, BARNES M, TANG H, et al.Kupffer cells in the liver[J].Compr Physiol, 2013, 3 (2) :785-797.
|
|
[17]SICA A, INVERNIZZI P, MANTOVANI A.Macrophage plasticity and polarization in liver homeostasis and pathology[J].Hepatology, 2014, 59 (5) :2034-2042.
|
|
[18]QUIGLEY EM, ABU-SHANAB A, MURPHY EF, et al.The metabolic role of the microbiome:implications for nafld and the metabolic syndrome[J].Semin Liver Dis, 2016, 36 (4) :312-316.
|
|
[19]DOULBERIS M, KOTRONIS G, GIALAMPRINOU D, et al.Non-alcoholic fatty liver disease:an update with special focus on the role of gut microbiota[J].Metabolism, 2017, 71:182-197.
|
|
[20]HE X, JI G, JIA W, et al.Gut microbiota and nonalcoholic fatty liver disease:insights on mechanism and application of metabolomics[J].Int J Mol Sci, 2016, 17 (3) :300.
|
|
[21]LEY RE, BCKHED F, TURNBAUGH P, et al.Obesity alters gut microbial ecology[J].Proc Natl Acad Sci U S A, 2005, 102 (31) :11070-11075.
|
|
[22]de FILIPPO C, CAVALIERI D, di PAOLA M, et al.Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa[J].Proc Natl Acad Sci U S A, 2010, 107 (33) :14691-14696.
|
|
[23]CHANG HC, GUARENTE L.SIRT1 and other sirtuins in metabolism[J].Trends Endocrinol Metab, 2014, 25 (3) :138-145.
|
|
[24]NASSIR F, IBDAH JA.et al.Sirtuins and nonalcoholic fatty liver disease[J].World J Gastroenterol, 2016, 22 (46) :10084-10092.
|
|
[25]DING RB, BAO J, DENG CX, et al.Emerging roles of SIRT1 in fatty liver diseases[J].Int J Biol Sci, 2017, 13 (7) :852-867.
|
|
[26]TOBITA T, GUZMAN-LEPE J, TAKEISHI K.et al.SIRT1 disruption in human fetal hepatocytes leads to increased accumulation of glucose and lipids[J].PLo S One, 2016, 11 (2) :e0149344.
|
|
[27]COLAK Y, YESIL A, MUTLU HH, et al.A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators[J].J Gastrointestin Liver Dis, 2014, 23 (3) :311-319.
|
|
[28]YILMAZ B, SAHIN K, BILEN H, et al.Carotenoids and non-alcoholic fatty liver disease[J].Hepatobiliary Surg Nutr, 2015, 4 (3) :161-171.
|
|
[29]OSEINI AM, SANYAL AJ.et al.Therapies in non-alcoholic steatohepatitis (NASH) [J].Liver Int, 2017, 37 (Suppl 1) :97-103.
|
|
[30]NI Y, NAGASHIMADA M, ZHUGE F, et al.Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice:a comparison with vitamin E[J].Sci Rep, 2015, 5:17192.
|
|
[31]CASTENMILLER JJ, WEST CE.Bioavailability and bioconversion of carotenoids[J].Annu Rev Nutr, 1998, 18:19-38.
|
|
[32]BURRI BJ, LA FRANO MR, ZHU C.Absorption, metabolism, and functions ofβ-cryptoxanthin[J].Nutr Rev, 2016, 74 (2) :69-82.
|
|
[33]HAEGELE AD, GILLETTE C, O'NEILL C, et al.Plasma xanthophyll carotenoids correlate inversely with indices of oxidative DNAdamage and lipid peroxidation[J].Cancer Epidemiol Biomarkers Prev, 2000, 9 (4) :421-425.
|
|
[34]SUGIURA M, NAKAMURA M, OGAWA K, et al.High serum carotenoids associated with lower risk for the metabolic syndrome and its components among Japanese subjects:Mikkabi cohort study[J].Br J Nutr, 2015, 114 (10) :1674-1682.
|
|
[35]KATSUURA S, IMAMURA T, BANDO N, et al.beta-Carotene and beta-cryptoxanthin but not lutein evoke redox and immune changes in RAW264 murine macrophages[J].Mol Nutr Food Res, 2009, 53 (11) :1396-1405.
|
|
[36]TAKAYANAGI K.Prevention of adiposity by the oral administration ofβ-cryptoxanthin[J].Front Neurol, 2011, 2:67.
|
|
[37]KOBORI M, NI Y, TAKAHASHI Y, et al.β-Cryptoxanthin alleviates diet-induced nonalcoholic steatohepatitis by suppressing inflammatory gene expression in mice[J].PLo S One, 2014, 9 (5) :e98294.
|
|
[38]CHEN JT, KOTANI K.Astaxanthin as a potential protector of liver function:a review[J].J Clin Med Res, 2016, 8 (10) :701-704.
|
|
[39]YANG Y, BAE M, KIM B.Astaxanthin prevents and reverses the activation of mouse primary hepatic stellate cells[J].J Nutr Biochem, 2016, 29:21-26.
|
|
[40]KOBORI M, TAKAHASHI Y, SAKURAI M, et al.Hepatic transcriptome profiles of mice with diet-induced nonalcoholic steatohepatitis treated with astaxanthin and vitamin E[J].Int J Mol Sci, 2017, 18 (3) :e593.
|
|
[41] FERRAMOSCA A, di GIACOMO M, ZARA V.Antioxidant dietary approach in treatment of fatty liver:new insights and updates[J].World J Gastroenterol, 2017, 23 (23) :4146-4157.
|
|
[42]LISBOA QC, COSTA SM, COUTO CA.Current management of non-alcoholic fatty liver disease[J].Rev Assoc Med Bras, 2016, 2 (9) :872-878.
|
|
[43]TAKAHASHI Y, SUGIMOTO K, INUI H, et al.Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J].World J Gastroenterol, 2015, 21 (13) :3777-3785.
|
|
[44]ZENG T, ZHANG CL, ZHAO XL, et al.Pentoxifylline for the treatment of nonalcoholic fatty liver disease:a meta-analysis of randomized double-blind, placebo-controlled studies[J].Eur JGastroenterol Hepatol, 2014, 26 (6) :646-653.
|
|
[45]DU J, MA YY, YU CH, et al.Effects of pentoxifylline on nonalcoholic fatty liver disease:A meta-analysis[J].World J Gastroenterol, 2014, 20 (2) :569-577.
|
|
[46]KANURI G, LANDMANN M, PRIEBS J, et al.Moderate alcohol consumption diminishes the development of non-alcoholic fatty liver disease (NAFLD) in ob/ob mice[J].Eur J Nutr, 2016, 55 (3) :1153-1164.
|
|
[47]FAGHIHZADEH F, ADIBI P, HEKMATDOOST A.The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease:a randomised, doubleblind, placebo-controlled study[J].Br J Nutr, 2015, 114 (5) :796-803.
|
|
[48]ELGEBALY A, RADWAN IA, ABOELNAS MM, et al.Resveratrol supplementation in patients with non-alcoholic fatty liver disease:systematic review and meta-analysis[J].J Gastrointestin Liver Dis, 2017, 26 (1) :59-67.
|
DownLoad: